Xizang Haisco Pharmaceutical Group Co Ltd (002653) - Net Assets
Based on the latest financial reports, Xizang Haisco Pharmaceutical Group Co Ltd (002653) has net assets worth CN¥4.84 Billion CNY (≈ $708.59 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥7.66 Billion ≈ $1.12 Billion USD) and total liabilities (CN¥2.82 Billion ≈ $412.25 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Xizang Haisco Pharmaceutical Group Co Lt to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥4.84 Billion |
| % of Total Assets | 63.22% |
| Annual Growth Rate | 19.25% |
| 5-Year Change | 46.83% |
| 10-Year Change | 90.98% |
| Growth Volatility | 61.65 |
Xizang Haisco Pharmaceutical Group Co Ltd - Net Assets Trend (2008–2025)
This chart illustrates how Xizang Haisco Pharmaceutical Group Co Ltd's net assets have evolved over time, based on quarterly financial data. See Xizang Haisco Pharmaceutical Group Co Lt defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Xizang Haisco Pharmaceutical Group Co Ltd (2008–2025)
The table below shows the annual net assets of Xizang Haisco Pharmaceutical Group Co Ltd from 2008 to 2025. For live valuation and market cap data, see market cap of Xizang Haisco Pharmaceutical Group Co Lt.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥4.29 Billion ≈ $627.44 Million |
+2.04% |
| 2024-12-31 | CN¥4.20 Billion ≈ $614.92 Million |
+0.76% |
| 2023-12-31 | CN¥4.17 Billion ≈ $610.28 Million |
+33.11% |
| 2022-12-31 | CN¥3.13 Billion ≈ $458.49 Million |
+7.30% |
| 2021-12-31 | CN¥2.92 Billion ≈ $427.32 Million |
+2.29% |
| 2020-12-31 | CN¥2.85 Billion ≈ $417.74 Million |
+20.12% |
| 2019-12-31 | CN¥2.38 Billion ≈ $347.78 Million |
+19.17% |
| 2018-12-31 | CN¥1.99 Billion ≈ $291.83 Million |
+1.22% |
| 2017-12-31 | CN¥1.97 Billion ≈ $288.32 Million |
-12.24% |
| 2016-12-31 | CN¥2.25 Billion ≈ $328.53 Million |
+4.10% |
| 2015-12-31 | CN¥2.16 Billion ≈ $315.58 Million |
+2.34% |
| 2014-12-31 | CN¥2.11 Billion ≈ $308.37 Million |
+9.36% |
| 2013-12-31 | CN¥1.93 Billion ≈ $281.97 Million |
+12.83% |
| 2012-12-31 | CN¥1.71 Billion ≈ $249.91 Million |
+122.44% |
| 2011-12-31 | CN¥767.76 Million ≈ $112.35 Million |
+69.45% |
| 2010-12-31 | CN¥453.09 Million ≈ $66.30 Million |
+235.19% |
| 2009-12-31 | CN¥135.17 Million ≈ $19.78 Million |
-37.12% |
| 2008-12-31 | CN¥214.95 Million ≈ $31.45 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Xizang Haisco Pharmaceutical Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 775.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.69 Billion | 39.42% |
| Other Components | CN¥2.60 Billion | 60.58% |
| Total Equity | CN¥4.29 Billion | 100.00% |
Xizang Haisco Pharmaceutical Group Co Ltd Competitors by Market Cap
The table below lists competitors of Xizang Haisco Pharmaceutical Group Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenzhen Transsion Holdings Co Ltd
SHG:688036
|
$9.36 Billion |
|
Waaree Energies Limited
NSE:WAAREEENER
|
$9.36 Billion |
|
Puig Brands SA
MC:PUIG
|
$9.36 Billion |
|
Maxscend Microelectronics Co Ltd
SHE:300782
|
$9.37 Billion |
|
Tempus AI, Inc. Class A Common Stock
NASDAQ:TEM
|
$9.34 Billion |
|
Masimo Corporation
NASDAQ:MASI
|
$9.34 Billion |
|
FSN E-Commerce Ventures Limited
NSE:NYKAA
|
$9.33 Billion |
|
PayPay Corporation American Depository Shares
NASDAQ:PAYP
|
$9.33 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Xizang Haisco Pharmaceutical Group Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,213,333,603 to 4,289,831,872, a change of 76,498,269 (1.8%).
- Net income of 259,579,780 contributed positively to equity growth.
- Dividend payments of 333,147,759 reduced retained earnings.
- Other comprehensive income decreased equity by 492,940,268.
- Other factors increased equity by 643,006,516.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥259.58 Million | +6.05% |
| Dividends Paid | CN¥333.15 Million | -7.77% |
| Other Comprehensive Income | CN¥-492.94 Million | -11.49% |
| Other Changes | CN¥643.01 Million | +14.99% |
| Total Change | CN¥- | 1.82% |
Book Value vs Market Value Analysis
This analysis compares Xizang Haisco Pharmaceutical Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 14.91x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 241.24x to 14.91x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | CN¥0.24 | CN¥57.10 | x |
| 2009-12-31 | CN¥0.15 | CN¥57.10 | x |
| 2010-12-31 | CN¥0.48 | CN¥57.10 | x |
| 2011-12-31 | CN¥0.79 | CN¥57.10 | x |
| 2012-12-31 | CN¥1.58 | CN¥57.10 | x |
| 2013-12-31 | CN¥1.78 | CN¥57.10 | x |
| 2014-12-31 | CN¥1.96 | CN¥57.10 | x |
| 2015-12-31 | CN¥2.03 | CN¥57.10 | x |
| 2016-12-31 | CN¥2.09 | CN¥57.10 | x |
| 2017-12-31 | CN¥1.84 | CN¥57.10 | x |
| 2018-12-31 | CN¥1.89 | CN¥57.10 | x |
| 2019-12-31 | CN¥2.22 | CN¥57.10 | x |
| 2020-12-31 | CN¥2.71 | CN¥57.10 | x |
| 2021-12-31 | CN¥2.64 | CN¥57.10 | x |
| 2022-12-31 | CN¥2.82 | CN¥57.10 | x |
| 2023-12-31 | CN¥3.82 | CN¥57.10 | x |
| 2024-12-31 | CN¥3.76 | CN¥57.10 | x |
| 2025-12-31 | CN¥3.83 | CN¥57.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Xizang Haisco Pharmaceutical Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.05%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.92%
- • Asset Turnover: 0.63x
- • Equity Multiplier: 1.63x
- Recent ROE (6.05%) is below the historical average (35.27%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 90.76% | 54.38% | 1.01x | 1.65x | CN¥173.59 Million |
| 2009 | 209.89% | 58.55% | 1.39x | 2.58x | CN¥270.20 Million |
| 2010 | 67.48% | 52.57% | 0.92x | 1.39x | CN¥260.44 Million |
| 2011 | 40.68% | 51.67% | 0.68x | 1.15x | CN¥235.52 Million |
| 2012 | 25.94% | 55.24% | 0.41x | 1.14x | CN¥272.28 Million |
| 2013 | 26.95% | 52.32% | 0.40x | 1.28x | CN¥326.52 Million |
| 2014 | 21.38% | 37.22% | 0.42x | 1.36x | CN¥239.80 Million |
| 2015 | 17.26% | 30.69% | 0.38x | 1.50x | CN¥156.50 Million |
| 2016 | 19.65% | 30.84% | 0.38x | 1.66x | CN¥217.50 Million |
| 2017 | 11.96% | 12.80% | 0.45x | 2.07x | CN¥38.99 Million |
| 2018 | 16.44% | 9.72% | 0.78x | 2.15x | CN¥130.56 Million |
| 2019 | 20.83% | 12.54% | 0.78x | 2.12x | CN¥256.76 Million |
| 2020 | 21.93% | 19.12% | 0.67x | 1.72x | CN¥346.38 Million |
| 2021 | 12.14% | 12.44% | 0.55x | 1.76x | CN¥60.87 Million |
| 2022 | 9.13% | 9.19% | 0.50x | 1.99x | CN¥-26.49 Million |
| 2023 | 7.06% | 8.80% | 0.50x | 1.59x | CN¥-122.88 Million |
| 2024 | 9.39% | 10.63% | 0.55x | 1.61x | CN¥-25.88 Million |
| 2025 | 6.05% | 5.92% | 0.63x | 1.63x | CN¥-169.40 Million |
Industry Comparison
This section compares Xizang Haisco Pharmaceutical Group Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $3,149,922,135
- Average return on equity (ROE) among peers: -7.89%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Xizang Haisco Pharmaceutical Group Co Ltd (002653) | CN¥4.84 Billion | 90.76% | 0.58x | $9.36 Billion |
| Shenzhen CAU Technology Co Ltd (000004) | $352.52 Million | -169.05% | 0.63x | $5.04 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $7.92 Billion | 9.41% | 0.17x | $1.30 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $114.46 Million | 16.43% | 1.34x | $363.16 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $721.59 Million | 0.83% | 0.13x | $494.15 Million |
| Chengzhi Shareholding Co Ltd (000990) | $783.92 Million | 7.05% | 0.80x | $1.51 Billion |
| Hualan Biological EngineeringInc (002007) | $4.44 Billion | 17.59% | 0.05x | $3.38 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $1.04 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $11.73 Billion | 13.75% | 0.13x | $4.33 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.00 Billion | 6.64% | 0.50x | $490.62 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $1.35 Billion | 14.07% | 0.06x | $1.61 Billion |
About Xizang Haisco Pharmaceutical Group Co Ltd
Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in China. It offers pharmaceutical products in the areas of anesthesia and analgesic, endocrine system, enteral parenteral nutrition, cardiovascular, psychiatric, tumor-related, digestive liver, and other diseases. Haisco Pharmaceutical Group Co., Ltd. has licensing and research c… Read more